peter
sherk
md
ronald
f
grossman
md
frcpc
chronic
obstruct
pulmonari
diseas
copd
character
presenc
airflow
obstruct
caus
chronic
bronchiti
emphysema
airflow
obstruct
gener
progress
may
accompani
airway
hyperreact
often
partial
reersibl
declin
lung
function
almost
univers
caus
decad
tobacco
smoke
exposur
develop
insidi
patient
often
complain
exert
dyspnea
forc
expiratori
volum
fev
predict
fev
fall
l
patient
disabl
activ
daili
live
surviv
approxim
forc
expiratori
volum
second
declin
mlyear
healthi
nonsmok
wherea
averag
declin
approxim
mlyear
approxim
smoker
suscept
airway
effect
smoke
develop
copd
patient
show
acceler
rate
declin
fev
l
e
r
approxim
million
american
suffer
copd
estim
increas
sinc
j
rank
fourth
among
lead
caus
death
north
america
lead
caus
death
rise
preval
j
accord
estim
made
nation
heart
lung
blood
institut
annual
total
cost
aris
copd
nearli
billion
dollar
amount
includ
almost
billion
direct
health
care
expenditur
nearli
billion
indirect
morbid
cost
billion
indirect
mortal
cost
period
rel
clinic
stabil
cours
copd
interrupt
recurr
exacerb
definit
acut
exacerb
copd
aecopd
imprecis
gener
consid
clinic
episod
increas
dyspnea
sputum
product
sputum
purul
patient
copd
symptom
sever
accompani
signific
hypoxemia
hypercapnia
patient
may
requir
hospit
articl
focus
primarili
manag
hospit
patient
aecopd
outsid
intens
care
unit
review
evid
support
avail
therapi
copd
exacerb
cigarett
smoke
import
caus
smoke
compromis
local
airway
defens
mechan
damag
ciliat
airway
epithelium
increas
mucu
viscos
slow
mucociliari
clearanc
condit
promot
bacteri
colon
lower
respiratori
tract
three
major
bacteri
pathogen
isol
patient
copd
period
clinic
stabil
exacerb
nontyp
haemophilu
influenza
streptococcu
pneumonia
moraxella
cafarhali
fev
sever
reduc
enterobacteriacea
pseudomona
aeruginosa
also
commonli
organ
possess
wide
array
virul
factor
allow
evad
clearanc
lower
airway
although
detail
discuss
bacteri
mechan
colon
infect
beyond
scope
articl
sever
concept
noteworthi
smoker
prone
acut
episod
bronchiti
greater
degre
bacteri
adher
oropharyng
airway
epitheli
cell
compar
nonsmok
adher
mucu
epitheli
cell
pathogen
bacteria
elabor
exoproduct
stimul
excess
mucou
product
disorgan
slow
ciliari
damag
epitheli
impair
immun
effectorcel
function
furthermor
bacteri
proteas
destroy
local
immunoglobulin
bacteria
loiter
airway
host
inflammatori
respons
stimul
movement
larg
number
neutrophil
subsequ
releas
proteas
toxic
oxygen
radic
epitheli
surfac
damag
may
enhanc
incit
impact
smoke
bacteri
colon
therefor
beget
airway
damag
turn
beget
inflamm
bacteri
colon
event
viciou
circl
hypothesi
propos
explain
bacteriahost
interact
establish
insidi
loss
lung
disord
pulmonari
ga
exchang
characterist
acut
exacerb
copd
patient
typic
found
sever
hypoxemia
without
hypercarbia
varieti
infecti
noninfecti
insult
result
inflamm
bronchospasm
mucou
hypersecret
lead
acut
airway
narrow
aggrav
ventilationperfus
v
q
mismatch
worsen
exist
hyperinfl
although
v
q
inequ
import
determin
hypoxemia
low
mix
venou
oxygen
tension
pvo
contribut
exacerb
work
breath
increas
overcom
increas
airway
resist
dynam
hyperinfl
oxygen
util
respiratori
muscl
therefor
markedli
increas
result
lower
fortun
among
patient
adequ
cardiac
reserv
increas
cardiac
output
partli
compens
diminish
pvoz
defend
arteri
oxygen
among
mechan
lead
hypercarbia
v
q
mismatch
probabl
import
hypoventil
least
among
patient
recov
exacerb
without
need
mechan
ventil
concept
support
observ
exacerb
patient
often
hypercarb
despit
increas
minut
ventil
hypoventil
may
addit
mechan
hypercarbia
respiratori
muscl
fatigu
acut
respiratori
failur
ensu
relationshp
bacteri
infect
copd
exacerb
precis
understood
sever
line
evid
howev
establish
import
role
bacteri
infect
mani
exacerb
high
titer
antibodi
nontyp
h
r
r
h
l
found
follow
aecopd
although
bacteri
colon
distal
airway
common
stabl
copd
patient
exacerb
often
higher
number
organ
tabl
summar
studi
use
protect
specimen
brush
defin
microflora
distal
airway
copd
exacerb
et
found
posit
bacteri
cultur
outpati
aecopd
compar
stabl
patient
exacerb
patient
twice
like
posit
cultur
ie
cfuml
five
time
like
bacteri
count
greater
likewis
pneumonia
like
found
sputum
exacerb
remiss
fagon
et
found
evid
bacteri
infect
patient
requir
mechan
ventil
streptococcu
pneumonia
h
influenza
cafarrhali
enter
gramneg
organ
collect
account
isol
investig
attempt
identifi
pneumonia
c
pneumonia
respiratori
virus
interestingli
gramneg
bacteria
account
isol
nearli
half
h
parainfluenza
yet
similar
studi
employ
protect
brush
specimen
detect
h
parainfluenza
among
patient
copd
moreov
smith
et
p
unabl
demonstr
rise
antibodi
h
parainfluenza
follow
copdrel
acut
respiratori
ill
seem
justifi
therefor
consid
h
parainfluenza
gener
nonpathogen
contrast
find
fagon
et
al
comprehens
microbiolog
survey
patient
sever
exacerb
found
higher
incid
potenti
pathogen
overal
patient
least
one
posit
bacteri
cultur
posit
serolog
c
pneumonia
respiratori
virus
cultur
obtain
within
hour
admiss
therebi
reduc
likelihood
nosocomi
infect
streptococcu
pneumonia
h
influenza
cafarrhali
account
potenti
pathogen
strikingli
gramneg
enter
bacteria
pseudomona
stenotrophomona
repres
potenti
studi
suggest
broader
profil
potenti
pathogen
may
present
among
patient
copd
sever
exacerb
although
find
confirm
larger
studi
choic
empir
antibiot
patient
aecopd
base
part
degre
exacerb
sever
broaderspectrum
initi
coverag
may
warrant
patient
aecopd
present
respiratori
failur
requir
mechan
ventil
sourc
bacteri
infect
copd
exacerb
may
endogen
exogen
small
group
patient
follow
year
exacerb
coincid
reinfect
strain
h
influenza
either
ie
endogen
differ
ie
exogen
dna
fingerprint
strain
h
influenza
shown
persist
sever
month
antibiot
treatment
effect
erad
estim
proport
copd
exacerb
associ
viral
infect
rang
larg
discrep
signific
differ
studi
sever
studi
lack
adequ
control
fail
record
frequenc
viral
infect
exacerbationfre
period
other
sommervil
stenhous
attempt
detect
select
pathogen
variabl
definit
exacerb
anoth
factor
may
affect
percentag
exacerb
caus
viral
ill
final
differ
serolog
isol
techniqu
account
varieti
studi
three
rigor
studi
summar
tabl
proport
exacerb
attribut
viral
mycoplasma
ill
rang
influenza
parainfluenza
coronaviru
frequent
pathogen
significantli
associ
exacerb
recent
goh
et
p
perform
prospect
etiolog
studi
inpati
aecopd
collect
pair
sera
influenza
b
parainfluenza
virus
well
legionella
mycoplasma
chlamydia
posit
serolog
found
patient
patient
viral
infect
common
organ
influenza
patient
demonstr
posit
serolog
five
patient
posit
serolog
legionella
wherea
evid
found
infect
caus
mycoplasma
gump
et
observ
patient
everi
week
year
document
exacerb
deriv
strike
correl
infect
exacerb
interpret
data
timeweight
analysi
found
incid
infect
per
patient
week
exacerb
ver
patient
week
remiss
aniiysi
buscho
et
found
exacerb
associ
viral
infect
rate
twice
viral
infect
remiss
detect
asymptomat
fourfold
rise
antivir
antibodi
titer
largest
studi
smith
et
follow
patient
year
analyz
acut
respiratori
ill
associ
nonbacteri
infect
approxim
acut
respiratori
ill
illnessfre
period
contrast
work
buscho
gump
smith
et
note
high
rate
rhinovir
infect
uncontrol
studi
mcnamara
also
report
rhinovir
infect
associ
copd
exacerb
case
respect
common
cold
may
deleteri
effect
upon
lung
patient
copd
like
develop
increas
cough
lower
respiratori
tract
symptom
rhinovir
infect
healthi
smith
et
apz
perform
observ
studi
patient
assess
potenti
interact
viral
mycoplasm
bacteri
infect
patient
copd
calcul
ratio
number
observ
exacerb
number
expect
viral
bacteri
associ
haemophilu
influenza
pneumonia
isol
twice
often
expect
follow
influenza
viru
infect
mark
rise
titer
antibodi
h
influenza
associ
preced
viral
mycoplasma
infect
suggest
viral
infect
promot
increas
invas
h
influenza
subsequ
infect
rigor
perform
clinic
studi
interact
viral
bacteri
infect
aecopd
although
concept
virus
promot
secondari
bacteri
infect
seem
biolog
plausibl
support
anim
research
remain
unknown
often
bacteri
infect
aecopd
follow
incit
viral
infect
suspend
particul
matter
less
pm
diamet
mi
produc
vehicl
exhaust
mani
industri
process
sever
epidemiolog
studi
associ
elev
pm
level
wide
rang
respiratori
outcom
includ
reduc
pulmonari
function
increas
chronic
respiratori
symptom
rate
hospit
mortal
similar
associ
exist
pollut
notabl
sulfur
dioxid
nitrogen
dioxid
studi
report
small
increas
airborn
particl
produc
adjust
increas
emerg
room
admiss
copd
winter
summer
similar
rate
excess
hospit
copd
report
sydney
australia
detroit
michigan
birmingham
alabama
although
small
effect
repres
signific
public
health
concern
particularli
demonstr
pollut
level
current
airqual
standard
summari
forego
studi
impli
bacteri
pathogen
identifi
approxim
half
copd
exacerb
viral
pathogen
identifi
episod
poor
air
qualiti
may
account
slightli
episod
aecopd
mani
copd
exacerb
obviou
pathogen
precipit
caus
found
known
frequent
potenti
factor
medic
noncompli
coincident
event
pulmonari
embol
myocardi
infarct
play
incit
role
aecopd
inde
often
difficult
distinguish
clinic
exacerb
without
infecti
caus
distinct
discuss
subsequ
section
antibiot
therapi
smoke
cessat
import
intervent
manag
patient
copd
landmark
lung
health
studi
confirm
smoke
cessat
greatli
reduc
rate
fevl
declin
benefit
smoke
cessat
seen
even
patient
age
chronic
sputum
product
often
clear
within
week
stop
although
nicotin
replac
therapi
effect
approach
smoke
cessat
counsel
physician
shown
potent
intervert
year
influenza
complic
respons
hundr
thousand
excess
hospit
ten
thousand
excess
death
billion
dollar
health
care
c
ss
chronic
lung
diseas
especi
high
risk
consequ
influenza
despit
recommend
annual
influenza
vaccin
recent
studi
document
inadequ
vaccin
rate
risk
among
elderli
person
includ
chronic
lung
diseas
nichol
et
overwhelmingli
demonstr
efficaci
cost
effect
influenza
vaccin
serial
cohort
studi
patient
vaccin
associ
reduct
rate
hospit
acut
chronic
respiratori
condit
anoth
studi
authorsa
found
influenza
vaccin
associ
reduct
risk
death
caus
odd
ratio
confid
interv
ci
recent
metaanalysi
cohort
studi
conclud
estim
vaccin
efficaci
prevent
respiratori
ill
hospit
death
respet
data
clearli
affirm
influenza
vaccin
indispens
part
care
elderli
person
especi
copd
valu
pneumococc
vaccin
elderli
patient
copd
controversi
two
random
control
trial
evalu
vaccin
efficaci
among
patient
copd
unabl
show
statist
signific
protect
recent
metaanalysi
conclud
vaccin
provid
partial
protect
bacterem
pneumococc
pneumonia
import
outcom
includ
bronchiti
mortal
caus
pneumococc
infect
protect
benefit
seen
lowrisk
group
among
copd
highrisk
nevertheless
pneumococc
vaccin
continu
strongli
recommend
patient
copd
safe
found
provid
signific
benefit
patient
casecontrol
indirect
cohort
well
recent
random
populationbas
sever
addit
novel
strategi
reduc
acut
exacerb
copd
investig
exampl
bv
oral
immunostimul
agent
contain
lyophyl
fraction
eight
common
respiratori
pathogen
use
associ
reduct
incid
acut
exacerb
chronic
bronchiti
decreas
antibiot
use
among
elderli
institution
patient
one
trial
frequenc
exacerb
less
half
mani
day
hospit
given
placebo
anoth
trend
toward
fewer
hospit
respiratori
reason
among
receiv
immunostimul
drug
although
avail
north
america
bv
use
mani
year
europ
trial
requir
properli
defin
role
anoth
approach
subcutan
administr
hyaluron
acid
ha
glycosaminoglycan
neutrophilregul
function
patient
chronic
bronchiti
fewer
acut
exacerb
bronchti
reduc
antibiot
use
note
among
hatreat
patient
placebocontrol
crossov
studi
investig
found
contin
administr
carbocystein
lysin
salt
monohydr
winter
month
effect
prevent
aecopd
reduc
antibiot
consumpt
patient
chronic
b
rn
c
h
despit
recent
intrigu
data
suggest
immunomodulatori
agent
may
attenu
develop
aecopd
random
control
trial
need
clarifi
potenti
role
routin
manag
patient
copd
follow
section
provid
overview
merit
lack
thereof
common
therapeut
intervent
aecopd
control
oxygen
bronchodil
antibiot
corticosteroid
noninvas
ventil
nutrit
support
chest
physiotherapi
discuss
avail
evid
random
control
trial
present
hypoxemia
immedi
threat
life
patient
aecopd
hypercapnia
wellrecogn
consequ
therapi
past
risk
hypoventil
even
apnea
result
administr
vastli
overestim
notion
commonli
induc
clinic
import
hypercarbia
acidosi
discredit
tradit
concept
correct
hypoxemia
supplement
oz
remov
hypox
drive
breath
lead
fall
minut
ventil
subsequ
carbon
dioxid
co
aubier
et
found
although
administr
supplement
oz
reduc
minut
ventil
increas
arteri
partial
pressur
carbon
dioxid
paco
mouth
occlus
pressur
indic
central
respiratori
drive
significantli
higher
acut
exacerb
stabl
condit
drive
breath
therefor
remain
high
spite
oxygen
treatment
later
studi
author
patient
copd
acut
respiratori
failur
receiv
minut
abolish
hypox
drive
minut
ventil
fell
could
account
entir
increas
paco
author
conclud
rise
caus
increas
vdvt
ie
increas
deadspac
ventil
primari
mechan
ozinduc
hypercarbia
v
q
mismatch
perhap
loss
hypox
vasoconstrict
recent
work
dunn
et
challeng
aubier
conclus
defend
tradit
concept
hypoventil
rather
v
q
mismatch
blame
induc
hypercarbia
one
mechan
appear
contribut
albeit
minor
extent
haldan
effect
wherebi
co
displac
hemoglobin
caus
rise
pc
nevertheless
risk
acut
hypoxemia
far
outweigh
risk
sever
hypercarbia
supplement
administr
recommend
hypoxem
patient
aecopd
oxygen
initi
given
hypoxem
patient
aecopd
nasal
cannula
venturi
mask
nasal
cannula
use
flow
rate
lminut
gener
suffic
inspir
concentr
oxygen
fio
usual
increas
increas
l
minut
flow
vari
accord
patient
inspiratori
flow
rate
venturi
mask
precis
initi
set
deliv
fio
averag
pao
increas
mm
hg
fio
increas
room
air
mm
hg
fio
increas
target
pao
mm
hg
correspond
pao
nearcomplet
satur
hemoglobin
rare
overzeal
administr
produc
progress
hypercapnia
respiratori
reason
respons
must
assess
accord
arteri
blood
ga
ph
measur
obtain
baselin
within
minut
start
chang
concentr
pao
remain
intract
low
ph
drop
result
increas
paco
altern
strategi
improv
hypoxemia
respiratori
acidosi
must
devis
includ
maxim
bronchodil
use
assist
ventil
role
bronchodil
manag
stabl
copd
discuss
articl
ferguson
pharmacolog
therapi
copd
bronchodil
agent
specif
p
agonist
ipratropium
bromid
ib
also
play
central
role
manag
patient
aecopd
without
respiratori
failur
agent
gener
given
inhal
reduc
sideeffect
acut
set
nebul
tradit
prefer
metereddos
inhal
mdi
eas
drug
although
data
support
choic
either
p
agonist
ib
firstlin
therapi
acut
exacerb
p
agonist
usual
given
first
step
perhap
longer
time
peak
effect
given
recommend
dose
two
puff
ib
gener
produc
greater
bronchodil
p
agonit
ipratropium
bromid
p
agonist
often
use
togeth
acut
set
despit
lack
evid
randomizedcontrol
trial
efficaci
tandem
either
agent
alon
e
n
g
doubleblind
random
studi
involv
patient
aecopd
effect
mg
ib
mg
fenoterol
combin
two
agent
compar
three
regimen
result
improv
spirometr
function
minut
posttreat
combin
therapi
better
either
agent
alon
similarli
odriscol
et
ala
compar
nebul
salbutamol
mg
without
ib
mg
patient
aecopd
one
hour
follow
treatment
peak
expiratori
flow
rate
significantli
differ
other
examin
clinic
rather
spirometr
outcom
follow
combin
therapi
patient
randomli
assign
combin
isoetharin
ib
discharg
emerg
depart
averag
minut
sooner
receiv
isoetharin
author
attribut
time
save
approxim
five
puff
ib
interestingli
mean
discharg
fev
differ
two
studi
follow
patient
minut
moayyedi
et
recent
attempt
captur
longerterm
benefit
combin
therapi
compar
nebul
treatment
salbutamol
without
ib
among
inpati
aecopd
found
differ
durat
stay
subject
breathless
spirometr
valu
assess
period
consider
effort
made
establish
effect
method
deliv
bronchodil
drug
patient
acut
airflow
obstruct
deliveri
method
includ
mdi
without
spacer
devic
nebul
handheld
attach
face
mask
dri
powder
inhal
recent
systemat
review
random
studi
compar
mdi
nebul
administr
p
agonist
acut
exacerb
asthma
copd
found
two
method
reason
approach
advoc
sever
worker
begin
nebul
treatment
among
patient
dyspneic
use
mdi
spacer
devic
r
r
e
c
l
earli
feasibl
patient
switch
mdi
result
consider
cost
savingsm
lzo
theophyllin
theophyllin
use
decad
amelior
symptom
patient
airflow
use
theophyllin
manag
stabl
copd
discuss
articl
ferguson
issu
theophyllin
releg
minor
role
acut
set
develop
safer
potent
bronchodil
l
lack
convinc
welldesign
trial
show
efficaci
contribut
declin
two
publish
studi
relat
specif
role
theophyllin
treatment
copd
exacerb
first
rice
et
small
yet
rigor
control
trial
patient
random
aminophyllin
infus
placebo
hospit
aecopd
drug
confer
increment
benefit
standard
care
either
subject
dyspnea
score
object
spirometri
outcom
measur
gastrointestin
side
effect
common
aminophyllin
group
emerg
departmentbas
studi
random
patient
acut
bronchospasm
receiv
either
aminophyllin
trial
includ
patient
asthma
copd
fail
report
number
unexpectedli
threefold
decreas
hospit
admiss
rate
patient
treat
aminophyllin
p
author
argu
aminophyllin
consid
select
patient
acut
exacerb
copd
asthma
reduc
hospit
would
decreas
cost
although
studi
illustr
potenti
import
clinic
benefit
theophyllin
cautiou
approach
necessari
effect
theophyllin
admiss
rate
primari
outcom
variabl
reduct
admiss
rate
quit
reach
statist
signific
adjust
multipl
comparison
even
though
magnitud
clinic
benefit
larg
theophyllin
produc
object
improv
pulmonari
function
measur
spirometri
despit
reserv
similar
report
clinic
benefit
absenc
statist
signific
spirometr
improv
found
studi
corticosteroid
acut
bronchodil
therapi
acut
bacteri
infect
contribut
exacerb
copd
infer
studi
demonstr
clinic
benefit
result
antibiot
therapi
antibiot
employ
prophylaxi
acut
treatment
aecopd
attent
given
prevent
exacerb
antibiot
murphi
sethim
review
nine
prospect
placebocontrol
trial
antibiot
prophylaxi
five
fail
show
reduct
frequenc
exacerb
although
two
demonstr
significantli
less
time
lost
work
among
patient
receiv
antibiot
contrast
compar
placebo
antibiot
prophylaxi
significantli
reduc
frequenc
exacerb
four
studi
investig
prophylaxi
seem
benefit
patient
suffer
largest
annual
number
exacerb
author
therefor
recent
suggest
antibiot
prophylaxi
may
appropri
individu
prone
frequent
exacerb
although
practic
recommend
part
regular
care
patient
copd
prescript
antibiot
facilit
earli
recoveri
aecopd
becom
routin
despit
unresolv
question
true
benefit
nicotra
et
random
inpati
aecopd
either
tetracyclin
placebo
week
day
differ
group
term
oxygen
lung
function
similar
larger
studi
outpati
uncompl
aecopd
jorgensedl
also
could
demonstr
clinic
import
advantag
amoxicillin
placebo
null
trial
notwithstand
highestqu
clinic
studi
date
anthonisen
et
al
conclud
antibiot
improv
outcom
random
outpati
receiv
either
placebo
broadspectrum
antibiot
amoxicillin
trimethoprimsulfamethoxazol
doxycyclin
copd
exacerb
exacerb
classifi
accord
sever
type
sever
defin
increas
dyspnea
sputum
volum
sputum
purul
type
involv
presenc
two
three
symptom
type
defin
presenc
one
three
symptom
addit
one
find
sore
throat
rhinorrhea
fever
increas
wheez
increas
cough
compar
placebo
antibiot
shorten
durat
exacerb
day
acceler
recoveri
peak
expiratori
flow
rate
p
treatment
success
defin
resolut
symptom
within
day
occur
placebo
group
patient
receiv
activ
treatment
p
significantli
among
patient
present
type
l
exacerb
clinic
deterior
twice
common
placebo
antibiot
clinician
therefor
would
need
treat
roughli
eight
exacerb
antibiot
achiev
one
treatment
success
beyond
chanc
two
order
avoid
singl
deterior
author
conclud
avoid
deleteri
outcom
strongest
reason
offer
antibiot
patient
aecopd
furthermor
state
antibiot
clearli
indic
type
exacerb
benefit
type
exacerb
probabl
justifi
patient
type
present
similar
find
report
anoth
largescal
random
trial
compar
amoxicillin
clavulan
placebo
saint
associ
systemat
review
clinic
efficaci
antibiot
aecopd
identifi
nine
random
placebocontrol
trial
antibiot
copd
exacerb
patient
follow
least
day
outcom
measur
common
nine
studi
author
deriv
overal
effect
size
quantifi
efficaci
antibiot
conclud
small
statist
signific
improv
could
expect
among
patient
receiv
antibiot
six
trial
report
peak
expiratori
flow
rate
overal
improv
liter
per
minut
favor
antibiot
group
note
although
small
effect
may
clinic
import
patient
sever
compromis
baselin
lung
function
prevent
respiratori
failur
hospit
intens
care
unit
icu
reduc
risk
treatment
failur
antibiot
select
accord
pertin
clinic
data
potenti
antimicrobi
resist
sever
scheme
propos
stratifi
patient
risk
select
appropri
therapi
simplest
recent
classif
system
present
tabl
g
r
sm
n
classifi
acut
exacerb
four
group
group
patient
acut
simpl
broncluti
like
viral
origin
anti
antibiot
therapi
direct
l
aeruginosa
commonli
drugresist
gramneg
bacteria
see
tabl
note
approach
antibiot
therapi
base
upon
ration
apprais
patient
risk
factor
like
pathogen
reduc
risk
treatment
failur
avoid
unnecessari
medic
econom
expens
outcom
data
suggest
approach
lead
improv
clinic
outcom
reduc
overal
retrospect
studi
destach
demonstr
compar
usual
firstlin
antibiot
treatment
acut
exacerb
chronic
bronchiti
use
newer
antibiot
reduc
hospit
rate
failur
rate
although
acquisit
cost
newer
antibiot
cephalosporin
macrolid
fluoroquinolon
higher
overal
cost
treat
patient
given
drug
lower
particular
group
receiv
amoxicillin
clavulan
azithromycin
ciprofloxacin
lowest
hospit
rate
clinic
failur
rate
cost
compar
cephalosporin
firstlin
therapi
hypothesi
aggress
antibiot
therapi
offer
highrisk
patient
test
recent
prospect
health
econom
studi
patient
least
three
treat
exacerb
chronic
bronchiti
past
year
random
receiv
either
ciprofloxacin
nonquinolonebas
therapi
next
acut
exacerb
clinic
endpoint
day
ill
hospit
time
next
exacerb
blend
qualityoflif
measur
nottingham
health
profil
st
georg
hospit
respiratori
questionnair
health
util
index
total
respiratori
cost
societ
perspect
although
overal
result
indic
advantag
either
treatment
arm
patient
risk
factor
sever
underli
lung
diseas
four
exacerb
per
year
durat
bronchiti
greater
year
elderli
signific
comorbid
ill
use
ciprofloxacin
led
improv
clinic
outcom
higher
qualiti
life
fewer
cost
result
studi
would
suggest
aggress
antimicrobi
therapi
direct
especi
toward
resist
organ
highrisk
patient
effect
strategi
therapi
therapi
older
antimicrobi
would
effect
usual
target
organ
particularli
plactamaseproduc
h
influenza
studi
need
clarifi
optim
antibiot
treatment
regimen
subgroup
patient
aecopd
random
control
trial
efficaci
corticosteroid
acut
exacerb
copd
summar
tabl
role
outpati
exacerb
evalu
one
small
compar
placebo
oral
prednison
mg
taper
mg
day
significantli
improv
airflow
oxygen
result
fewer
treatment
failur
fev
improv
averag
ml
per
day
among
patient
receiv
find
support
earlier
retrospect
data
suggest
among
patient
aecopd
present
emerg
depart
ed
incid
revisit
ed
within
hour
significantli
reduc
corticosteroid
corticosteroid
often
given
initi
ed
physician
sever
trial
examin
emerman
et
studi
effect
singl
dose
methylprednisolon
mg
intraven
iv
upon
pulmonari
function
hospit
rate
patient
ed
copd
exacerb
fail
show
improv
spirometri
decreas
rate
hospit
patient
treat
approxim
hour
singl
steroid
dose
short
period
observ
howev
postul
account
appar
lack
efficaci
steroid
recent
bullard
et
al
demonstr
benefici
effect
steroid
upon
flow
rate
earli
hour
initi
treatment
alberp
provid
initi
justif
routin
use
system
steroid
care
hospit
patient
copd
exacerb
fortyfour
patient
copd
acut
respiratori
insuffici
random
placebo
methylprednisolon
mg
kg
intraven
everi
hour
day
treat
steroid
significantli
like
achiev
greater
increas
fev
baselin
effect
observ
hour
follow
start
treatment
persist
hour
corticosteroid
improv
postbronchodil
lung
function
placebo
minim
effect
upon
total
symptom
anoth
small
trial
hospit
patient
random
receiv
placebo
mg
oral
prednisolon
day
although
studi
describ
establish
corticosteroid
significantli
increas
fev
short
term
studi
explicitli
design
captur
longerterm
endpoint
advers
consequ
associ
steroid
therapi
studi
hospit
patient
aecopd
given
placebo
methylprednisolon
mg
taper
mg
month
follow
month
discharg
mean
fev
fvc
valu
differ
treatment
group
end
studi
recent
niewoehn
et
ala
publish
import
system
corticosteroid
chronic
obstruct
pulmonari
diseas
exacerb
trial
perform
threeway
random
wherebi
patient
receiv
cours
glucocorticoid
receiv
cours
ceiv
placebo
steroid
result
faster
recoveri
fev
shorten
hospit
stay
day
p
day
steroid
therapi
reduc
treatment
failur
defin
death
caus
need
intub
readmiss
intensif
drug
therapi
approxim
differ
week
treatment
respect
spirometri
treatment
failur
rate
howev
dose
methylprednisolon
high
mg
everi
hour
day
result
significantli
hyperglycemia
possibl
increas
secondari
infect
rate
summari
evid
random
control
trial
support
conclus
among
patient
acut
exacerb
oral
intraven
corticosteroid
significantli
increas
fev
hour
like
reduc
risk
treatment
failur
prove
benefit
treatment
longer
week
hyperglycemia
common
shortterm
complic
steroid
treatment
studi
becom
avail
possibl
better
understand
riskbenefit
ratio
corticosteroid
metaanalysi
better
defin
optimum
dose
durat
also
import
investig
longterm
risk
advers
effect
intermitt
corticosteroid
patient
requir
recurr
exacerb
mani
year
time
noninvas
positivepressur
ventil
nppv
arguabl
signific
recent
advanc
care
patient
copd
acut
respiratori
failur
avoid
complic
endotrach
intub
preserv
airway
defens
mechan
allow
patient
eat
speak
expector
secret
acut
respiratori
failur
copd
often
character
viciou
circl
wherein
respiratori
muscl
must
meet
everincreas
ventilatori
demand
condit
worsen
hypoxemia
hypercapnia
acidosi
increas
metabol
requir
respiratori
muscl
match
commensur
rise
cardiac
output
acidosi
muscl
fatigu
ensu
allow
muscl
rest
nppv
interrupt
process
therebi
prevent
respiratori
arrest
deathn
tabl
summar
random
control
trial
nppv
aecopd
bott
et
random
patient
copd
hypoxemichypercarb
respiratori
failur
either
convent
treatment
volumecycl
nasal
nppv
patient
group
similar
pretreat
blood
ga
spirometr
abnorm
hour
signific
rise
ph
drop
nppv
group
compar
convent
treatment
nppv
also
result
significantli
less
breathless
day
importantli
howev
intentiontotreat
analysi
reveal
trend
toward
lower
mortal
nppv
group
versu
rel
risk
ci
p
ns
effect
becam
signific
exclud
four
patient
random
nppv
receiv
two
confus
one
unabl
breath
nose
one
activ
treatment
withdrawn
none
patient
random
nppv
requir
intub
seriou
complic
nppv
report
studi
critic
lack
standard
treatment
group
unusu
high
mortal
control
group
kramer
et
investig
impact
nppv
need
intub
among
patient
sever
hypercarb
respiratori
failur
copd
exacerb
sixteen
patient
copd
random
pressurelimit
nasal
nppv
addit
standard
care
patient
copd
receiv
standard
care
alon
clear
priori
indic
intub
given
significantli
five
patient
nppv
group
requir
intub
compar
standard
therapi
arm
furthermor
maxim
inspiratori
pressur
increas
significantli
nppv
arm
hour
indic
rapid
revers
diaphragmat
fatigu
contrast
work
bott
howev
signific
differ
treatment
group
time
first
hour
studi
underpow
detect
differ
mortal
recent
european
multicent
random
patient
standard
therapi
pressurelimit
nppv
face
mask
patient
requir
admiss
intens
care
unit
follow
death
hospit
discharg
noninvas
ventil
markedli
reduc
need
intub
control
versu
nppv
compar
standard
care
nppv
also
significantli
reduc
mortal
versu
complic
rate
versu
mean
durat
hospit
stay
day
versu
day
p
recent
celikel
et
compar
pressurelimit
nppv
face
mask
usual
care
among
patient
moder
sever
hypercarb
acut
respiratori
failur
copd
noninvas
positivepressur
ventil
result
significantli
fewer
treatment
failur
defin
need
intub
nppv
group
need
nppv
intub
control
group
hospit
stay
significantli
shorter
nppv
group
contrast
et
al
howev
unabl
demonstr
statist
signific
benefit
nasal
nppv
convent
treatment
term
durat
hospit
dyspnea
score
arteri
blood
ga
measur
maxim
inspiratori
pressur
patient
trial
howev
clearli
ill
studi
inde
patient
either
group
requir
intub
random
control
trial
nppv
treatment
aecopd
hypercarb
respiratori
failur
recent
review
systemati
pool
odd
ratio
intub
follow
nppv
ci
importantli
howev
trial
includ
mortal
outcom
collect
demonstr
strong
surviv
benefit
pool
odd
ratio
death
ci
therefor
worst
nppv
increas
patient
chanc
surviv
nearli
best
chanc
surviv
better
similar
patient
receiv
nppv
improv
ph
pacoz
within
hour
initi
nppv
good
level
conscious
begin
nppv
associ
success
respons
nppv
patient
aecopd
respiratori
acidoi
malnutrit
common
among
patient
copd
increas
morbid
mortal
associ
diseas
veteran
administr
cooper
studi
pulmonari
show
patient
fevl
less
equal
l
weigh
less
ideal
bodi
weight
ibw
compar
near
normal
bodi
weight
less
sever
impair
patient
anoth
patient
emphysema
found
weigh
less
ibw
furthermor
report
hospit
patient
copd
evid
weight
loss
pingletongl
found
among
ventil
patient
mortal
significantli
higher
poorli
nourish
better
nutrit
statu
poorli
nourish
patient
also
significantli
higher
frequenc
hypercapnia
princip
effect
malnutrit
upon
respiratori
system
thought
worsen
respiratori
muscl
function
impair
ventilatori
drive
immun
dysfunct
malnutrit
impair
muscl
function
reduc
avail
energi
substrat
glycogen
phosphat
alter
structur
muscl
fiber
combin
intercurr
airway
infect
mechan
disadvantag
diaphragm
copd
malnutrit
may
profound
effect
respiratori
muscl
mechan
experiment
evid
blunt
hypox
drive
respons
semistarv
suggest
anoth
mechan
patient
copd
may
predispos
respiratori
random
control
trial
demonstr
reduc
morbid
mortal
result
nutrit
support
acut
respiratori
failur
nevertheless
clinician
abl
identifi
malnourish
patient
understand
goal
nutrit
therapi
particular
attent
paid
patient
hypercatabol
state
increas
risk
proteincalori
malnutrit
subject
global
assess
harrisbenedict
equat
two
valid
clinic
instrument
assess
malnutrit
plan
nutrit
therapi
review
elsewher
gener
goal
nutrit
supplement
among
patient
acut
respiratori
failur
consist
maintain
bodi
weight
prevent
protein
breakdown
effect
malnutrit
nutrit
supplement
patient
copd
discuss
detail
articl
schol
wouter
issu
valu
chest
physiotherapi
postur
drainag
without
chest
percuss
aecopd
demonstr
studi
patient
aecopd
fail
demonstr
benefici
effect
chest
physiotherapi
upon
sputum
volum
ga
exchang
one
document
transient
signific
decreas
fev
result
bronchoconstrict
follow
chest
percuss
vibrat
evid
suggest
patient
larger
volum
airway
secret
mld
particularli
bronchiectasi
may
benefit
guidelin
therefor
chest
physiotherapi
advoc
ituat
gener
howev
recommend
routin
manag
although
outcom
data
import
caution
requir
interpret
data
gener
observ
larg
number
patient
typic
tertiari
referr
center
pertin
data
individu
patient
may
limit
especi
outsid
major
center
copd
exacerb
studi
prognosi
patient
copd
acut
respiratori
failur
perform
previou
decad
less
relev
today
standard
current
outcom
appear
better
past
part
widespread
use
control
oz
therapi
corticosteroid
ib
avail
better
p
agonist
reduc
use
methylxanthin
increas
use
noninvas
ventilatori
inde
evid
support
trend
toward
improv
surviv
hypercapn
respiratori
failur
past
year
mortal
rate
studi
surviv
acut
respiratori
failur
copd
conduct
rang
overal
mortal
similar
studi
rang
overal
mortal
recent
comprehens
evalu
outcom
follow
aecopd
publish
connor
et
compon
landmark
studi
understand
prognos
outcom
risk
treatment
support
prospect
studi
patient
admit
five
us
tertiari
care
hospit
sever
hypercarb
copd
exacerb
initi
paco
mm
hg
baselin
fev
avail
patient
half
patient
requir
intens
care
unit
admiss
requir
mechan
ventil
hospit
mortal
strike
howev
find
follow
discharg
one
third
patient
die
within
month
one
half
within
year
surprisingli
patient
surviv
hospit
substanti
risk
discharg
facil
home
readmiss
acut
care
ensu
month
higher
acut
physiolog
score
acut
physiolog
chronic
health
evalu
apach
older
age
poor
function
statu
prior
admiss
independ
increas
risk
death
improv
surviv
predict
greater
bmi
albumin
level
higher
paoz
fio
surprisingli
presenc
cor
pulmonal
congest
heart
failur
caus
exacerb
latter
find
may
explain
good
respons
two
disord
acut
therapi
also
support
find
host
factor
princip
determin
outcom
aecopd
retrospect
analysi
exacerb
patient
copd
sever
airflow
obstruct
use
home
frequenc
exacerb
histori
previou
pneumonia
sinus
use
mainten
corticosteroid
independ
associ
treatment
failur
surprisingli
age
choic
antibiot
presenc
comorbid
condit
affect
treatment
outcom
studi
sever
l
oo
iw
evalu
prognosi
patient
copd
requir
icu
admiss
acut
exacerb
result
somewhat
contradictori
kaelin
et
exampl
use
sever
easili
obtain
indic
unabl
discrimin
patient
surviv
less
month
follow
intub
analysi
consecut
acut
copd
exacerb
neither
age
spirometr
blood
ga
nutrit
indic
predict
surviv
contrast
menzi
et
report
among
patient
higher
baselin
fev
serum
albumin
significantli
associ
improv
surviv
follow
mechan
ventil
contradictori
find
especi
curiou
given
studi
similar
inclus
exclus
criteria
period
observ
moreov
popul
mean
percentpredict
fev
nearli
ident
baselin
valu
serum
albumin
recent
riev
et
alloo
tri
identifi
clinic
use
variabl
predict
success
wean
mechan
ventil
shortterm
surviv
patient
copd
acut
respiratori
failur
observ
episod
acut
respiratori
failur
patient
baselin
fev
greater
less
l
respect
cohort
sever
copd
surviv
wean
spontan
breath
hour
furthermor
group
surviv
absenc
infiltr
chest
radiograph
influenti
predictor
surviv
patient
sever
copd
pneumonia
account
infiltr
seen
group
baselin
fev
obtain
period
clinic
stabil
prior
episod
acut
respiratori
failur
avail
patient
extent
baselin
obstruct
alon
statist
correl
shortterm
surviv
either
group
combin
sever
baselin
obstruct
pulmonari
infiltr
markedli
increas
risk
death
outcom
follow
aecopd
associ
icu
admiss
respiratori
failur
studi
dewan
discuss
articl
sethi
issu
seneff
et
recent
refin
discuss
rel
prognost
valu
differ
clinic
variabl
follow
copd
exacerb
analyz
admiss
acut
copd
exacerb
apach
databas
hospit
mortal
patient
age
older
hospit
mortal
rate
respect
report
emphas
individu
clinic
variabl
differ
valu
predict
shortand
longterm
surviv
patient
age
exampl
statist
signific
determin
surviv
influenti
hospit
mortal
account
nonrespiratori
organ
dysfunct
similarli
presenc
hypercarbia
valu
predict
hospit
mortal
becam
import
long
term
mortal
rate
patient
admiss
less
mm
hg
versu
greater
mm
hg
respect
signific
predictor
short
longterm
mortal
develop
sever
multipl
organ
dysfunct
syndrom
respiratori
dysfunct
import
longer
term
author
state
case
acut
lifethreaten
compon
exacerb
revers
shortterm
death
avoid
mechan
ventil
appropri
treatment
howev
abnorm
respiratori
physiolog
reflect
underli
sever
lung
diseas
patient
greater
abnorm
surviv
hospit
greater
risk
subsequ
death
chronic
obstruct
pulmonari
diseas
lead
caus
death
rise
preval
medic
econom
cost
aris
acut
exacerb
copd
therefor
expect
increas
come
year
although
exacerb
may
initi
multipl
factor
common
identifi
associ
bacteri
viral
infect
associ
approxim
copd
exacerb
respect
addit
smoke
cessat
annual
influenza
vaccin
import
method
prevent
exacerb
control
import
intervent
patient
acut
hypox
respiratori
failu
evid
random
control
trial
justifi
use
corticosteroid
bronchodil
theophyllin
noninvas
positivepressur
ventil
select
patient
antibiot
particularli
sever
exacerb
antibiot
chosen
accord
patient
risk
treatment
failur
potenti
antibiot
resist
acut
set
combin
treatment
pagonist
anticholinerg
bronchodil
reason
support
random
control
studi
physician
identifi
possibl
correct
malnutrit
chest
physiotherapi
proven
role
manag
acut
exacerb
